Ignite Creation Date:
2026-03-26 @ 3:15 PM
Ignite Modification Date:
2026-03-30 @ 3:55 AM
Study NCT ID:
NCT07342192
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-01-15
First Post:
2025-12-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Radicle Clarity DSTTM: A Study Assessing the Impact of Health and Wellness Products on Mental Clarity and Related Health Outcomes
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR'], 'maskingDescription': "The investigator is blinded to the participants' assigned study products. Participants are blinded to the study product they received."}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Participants will be stratified based on their assigned sex at birth and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 990}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-01-21', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2027-01-21', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2026-01-07', 'studyFirstSubmitDate': '2025-12-19', 'studyFirstSubmitQcDate': '2026-01-07', 'lastUpdatePostDateStruct': {'date': '2026-01-15', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-01-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-01-21', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Minimal clinically important difference (MCID) in cognitive function', 'timeFrame': '13 weeks', 'description': 'Minimal clinically important difference (MCID) in cognitive function: Likelihood of experiencing minimal clinically important difference in cognitive function score as assessed by PROMIS Cognitive Function 8A (scale 8-40; where lower scores correspond to worse cognitive function)'}, {'measure': 'Minimal clinically important difference (MCID) in fatigue', 'timeFrame': '13 weeks', 'description': 'Minimal clinically important difference (MCID) in fatigue: Likelihood of experiencing minimal clinically important difference in fatigue score as assessed by PROMIS Fatigue 8A (scale 8-40; where higher scores correspond to more severe fatigue)'}, {'measure': 'Minimal clinically important difference (MCID) in sleep', 'timeFrame': '13 weeks', 'description': 'Minimal clinically important difference (MCID) in sleep: Likelihood of experiencing minimal clinically important difference in sleep score, as measured by PROMIS Sleep-Related Impairment 8a (scale 8-40; where the higher scores correspond to worse sleep)'}, {'measure': 'Minimal clinically important difference (MCID) in cognitive abilities', 'timeFrame': '13 weeks', 'description': 'Minimal clinically important difference (MCID) in cognitive abilities: Likelihood of experiencing minimal clinically important difference in cognitive abilities score as assessed by PROMIS Cognitive Function - Abilities 8a (scale 8-40; where the higher scores correspond to better cognitive abilities)'}], 'primaryOutcomes': [{'measure': 'Change in cognitive function', 'timeFrame': '13 weeks', 'description': 'Change in cognitive function: Difference in rates of change over time in cognitive function score as assessed by PROMIS Cognitive Function 8A (scale 8-40; where lower scores correspond to worse cognitive function)'}], 'secondaryOutcomes': [{'measure': 'Change in fatigue', 'timeFrame': '13 weeks', 'description': 'Change in fatigue: Difference in rates of change over time in fatigue score as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 8A (scale 8-40; where higher scores correspond to more severe fatigue)'}, {'measure': 'Change in sleep-related impairment', 'timeFrame': '13 weeks', 'description': 'Change in sleep-related impairment: Difference between rates of change over time in sleep score as assessed by PROMIS Sleep-Related Impairment 8a (scale 8-40; where the higher scores correspond to worse sleep)'}, {'measure': 'Change in cognitive abilities', 'timeFrame': '13 weeks', 'description': 'Change in cognitive abilities: Difference between rates of change over time in Cognitive Abilities score as assessed by PROMIS Cognitive Function - Abilities 8a (scale 8-40; where the higher scores correspond to better cognitive abilities)'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Cognitive Function']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.radiclescience.com', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'Radicle Clarity DSTTM: A randomized, double-blind, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on mental clarity and related health outcomes.', 'detailedDescription': 'This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States. Eligible participants will (1) have the opportunity for meaningful improvement (at least 30%) in their primary health outcome, and (2) express acceptance in taking a product and not knowing its formulation until the end of the study. Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.\n\nSelf-reported data are collected electronically from eligible participants for 12 weeks. Participant reports of health indicators will be collected at enrollment and throughout the active period of study product usage. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '60 Years', 'minimumAge': '35 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion\n\nParticipants must meet all the following criteria:\n\n* Adults, 35-60 years of age (inclusive) at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n\n * Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Expresses a willingness to take a study product and not know the product identity(active or placebo) until the end of the study\n\nExclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.\n\n * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n\n * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products\n* Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products and/or pose a safety risk\n* Lack of reliable daily access to the internet\n* Reports current use of prescription medication(s) for cognitive enhancement\n* Reports current regular cannabis use'}, 'identificationModule': {'nctId': 'NCT07342192', 'briefTitle': 'Radicle Clarity DSTTM: A Study Assessing the Impact of Health and Wellness Products on Mental Clarity and Related Health Outcomes', 'organization': {'class': 'INDUSTRY', 'fullName': 'Radicle Science'}, 'officialTitle': 'Radicle Clarity DSTTM: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Mental Clarity and Related Health Outcomes', 'orgStudyIdInfo': {'id': 'RADX_P_2601_DST'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo Clarity Control', 'description': 'Clarity Product Placebo Control', 'interventionNames': ['Dietary Supplement: Clarity Product Placebo Control']}, {'type': 'EXPERIMENTAL', 'label': 'RS Active Clarity Product', 'description': 'RS Active Clarity Product', 'interventionNames': ['Dietary Supplement: RS Clarity Active Product']}], 'interventions': [{'name': 'Clarity Product Placebo Control', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Participants will use their Clarity Product Placebo Control as directed for a period of 12 weeks.', 'armGroupLabels': ['Placebo Clarity Control']}, {'name': 'RS Clarity Active Product', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Participants will use their RS Clarity Active Product as directed for a period of 12 weeks', 'armGroupLabels': ['RS Active Clarity Product']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92014', 'city': 'Del Mar', 'state': 'California', 'country': 'United States', 'contacts': [{'name': 'Study Manager', 'role': 'CONTACT', 'email': 'studymgmt@radiclescience.com', 'phone': '760-281-3898'}, {'name': 'Megan Moseley', 'role': 'CONTACT', 'email': 'megan@radiclescience.com'}], 'facility': 'Radicle Science Inc.', 'geoPoint': {'lat': 32.95949, 'lon': -117.26531}}], 'centralContacts': [{'name': 'Study Manager', 'role': 'CONTACT', 'email': 'studymgmt@radiclescience.com', 'phone': '858-779-0086'}, {'name': 'Susan Hewlings', 'role': 'CONTACT', 'email': 'susan.hewlings@radiclescience.com', 'phone': '760-281-3898'}], 'overallOfficials': [{'name': 'Susan Hewlings', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Radicle Science'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'Data will not be shared with researchers outside of Radicle Collaborators on this study.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Radicle Science', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}